Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the approval notice for the marketing application of the chemical raw material drug Mirabegron from the National Medical Products Administration [1] Group 1 - The chemical raw material drug approved is named Mirabegron, which is a selective β-3 adrenergic receptor agonist [1] - Mirabegron is primarily used for the treatment of overactive bladder (OAB), including symptoms such as urinary incontinence, urgency, and frequency [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Mirabegron, a selective β-3 adrenergic receptor agonist, which is primarily used for treating overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Company Summary - Jincheng Pharmaceutical announced on September 23 that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received a notification from the National Medical Products Administration regarding the approval of the marketing application for the chemical raw material drug Mirabegron [1] Industry Summary - Mirabegron is classified as a selective β-3 adrenergic receptor agonist and is indicated for the treatment of overactive bladder (OAB), which includes symptoms like urinary incontinence, urgency, and frequency [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of Mirabegron active pharmaceutical ingredient, enhancing the company's product line and market competitiveness [1] Summary by Relevant Sections - **Approval Announcement** - The company announced that it has received the approval notice for the marketing application of Mirabegron active pharmaceutical ingredient [1] - **Product Information** - Mirabegron is a selective β-3 adrenergic receptor agonist primarily used for the treatment of overactive bladder [1] - **Market Data** - According to IMS data, the global consumption of Mirabegron active pharmaceutical ingredient is projected to be 57.91 tons in 2022, 63.05 tons in 2023, and 69.79 tons in 2024 [1] - **Strategic Implications** - The approval will enrich the company's active pharmaceutical ingredient product line and enhance its market competitiveness [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-064 化学原料药注册标准编号：YBY69552025 生产企业：北京金城泰尔制药有限公司 山东金城医药集团股份有限公司 关于子公司收到化学原料药上市申请批准 通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司（以下简称"公司"）之全资子公司北京金 城泰尔制药有限公司于近日收到国家药品监督管理局下发的《化学原料药上市申 请批准通知书》（通知书编号：2025YS00837）。现将相关情况公告如下： 一、药品的基本情况 化学原料药名称：米拉贝隆 包装规格：20kg/桶 山东金城医药集团股份有限公司董事会 申请事项：境内生产化学原料药上市申请 2025 年 9 月 23 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品相关信息 米拉贝隆为选择性β-3 肾上腺素受体激动剂，主要用于治疗包括尿失禁、尿 急和尿频在内的膀胱过度活动症（OAB）。目前包括公司在内，国内有 ...

Group 1 - The genetically modified (GM) concept sector declined by 0.79% as of the market close on September 16, ranking among the top declines in concept sectors, with companies like Batian Co., KQ Biotech, and Dunhuang Seed Industry experiencing significant drops [1] - The GM concept sector saw a net outflow of 153 million yuan in main funds today, with 13 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan. The stock with the highest net outflow was Shennong Seed Industry, with a net outflow of 30.19 million yuan [2] - Other companies with notable net outflows included Dunhuang Seed Industry, Nongfa Seed Industry, and Jincheng Pharmaceutical, with net outflows of 23.78 million yuan, 22.76 million yuan, and 21.20 million yuan respectively [2] Group 2 - The top net inflow stocks in the GM concept sector included KQ Biotech and Guotou Fengle, with net inflows of 4.89 million yuan and 0.99 million yuan respectively [3] - The GM concept sector's outflow leaderboard featured Shennong Seed Industry, Dunhuang Seed Industry, Nongfa Seed Industry, and Jincheng Pharmaceutical, all showing negative performance in terms of stock price changes [2][3]

证券日报网讯 9月10日晚间，金城医药发布公告称，2025年半年度权益分派方案为向全体股东每10股派 1元人民币现金（含税）。股权登记日为2025年9月16日，除权除息日为2025年9月17日。 （文章来源：证券日报） ...

证券代码：300233 证券简称：金城医药 公告编号：2025-063 山东金城医药集团股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、公司 2025 年半年度权益分派方案已获 2025 年 9 月 8 日召开的 2025 年第二次 临时股东大会审议通过，具体内容为：以截至 2025 年 6 月 30 日公司总股本 383,874,587 股扣除回购专用账户中 4,543,000 股后的 379,331,587 股为基数，向全 体股东每 10 股派发现金红利人民币 1.00 元（含税），预计派发现金红利人民币 37,933,158.70 元（含税）；除前述现金分红外，本次利润分配不送红股，不以资本 公积金转增股本。 2、因公司回购专户的股份不享有参与利润分配的权利，公司本次实际派发现金 分红总额=（383,874,587 股-4,543,000 股）÷10 股×1.00 元=37,933,158.70 元。本 次权益分派实施后计算除权除息价格时，按总股本（含回购股份，下同）计算的每 10 股派息 ...

北京市中伦（青岛）律师事务所 关于山东金城医药集团股份有限公司 2025 年第二次临时股东大会的 法律意见书 二〇二五年九月 北京市中伦（青岛）律师事务所 关于山东金城医药集团股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：山东金城医药集团股份有限公司 北京市中伦（青岛）律师事务所（以下简称"本所"）接受山东金城医药集团 股份有限公司（以下简称"公司"）的委托，根据本法律意见书出具日前已经发生 或存在的事实和《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》《律 师事务所从事证券法律业务管理办法》《律师事务所证券法律业务执业规则（试 行）》等中华人民共和国（以下简称"中国"，为本法律意见书之目的，不包括中 华人民共和国拥有主权的香港特别行政区、澳门特别行政区和台湾地区）现行有 效的法律、法规和规范性文件以及《山东金城医药集团股份有限公司章程》（以 下简称"《公司章程》"）、《山东金城医药集团股份有限公司股东大会议事规则》 （以下简称"《股东大会议事规则》"）等有关规定，指派律师出席公司于 2025 年 9 月 8 日 ...

山东金城医药集团股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300233 证券简称：金城医药 公告编号：2025-062 1、本次股东大会不存在增加、变更、否决议案的情况； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间：2025 年 9 月 8 日（星期一）14:30 2、召开地点：山东省淄博市淄川经济开发区双山路 1 号会议中心 3、召开方式：现场结合网络 4、召集人：董事会 5、主持人：董事长赵叶青 本次会议的召集、召开符合《中华人民共和国公司法》《上市公司股东会规 则》《深圳证券交易所创业板股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《山东金城医药集团股份有限公司章程》的有关规定。 通过网络投票的股东 250 人，代表股份 4,496,398 股，占公司有表决权股份 总数的 1.1853％。 2、中小股东出席的总体情况 通过现场和网络投票的中小股东 249 人，代表股份 4,480,498 股， ...

Core Insights - The global oral tobacco market is projected to reach $11.232 billion in 2024, reflecting a year-on-year growth of 57.57%, and is expected to grow to $25.148 billion by 2028, with a CAGR of 22.32% from 2024 to 2028 [1][2] - The North American and European markets are experiencing high growth rates, while the Asian and African markets are in early stages, indicating significant potential for rapid development in emerging markets [1][2] - The FDA's approval of flavored oral tobacco products is anticipated to act as a catalyst for market growth, potentially increasing the overall market ceiling [1][4] Market Overview - The retail market for oral tobacco is highly concentrated, with Philip Morris International, British American Tobacco, and Altria Group holding market shares of 41.1%, 24.6%, and 13.8% respectively, totaling 79.5% of the market [2] - In 2024, the North American oral tobacco market is expected to reach $8.775 billion, growing by 58.30% year-on-year, while the European market is projected to reach $2.415 billion, with a year-on-year growth of 56.12% [1][2] Company Performance - Philip Morris International's ZYN nicotine pouch sales are projected to be 644 million boxes in 2024, a year-on-year increase of 52.93%, with U.S. sales accounting for 581 million boxes, up 51.49% [2] - British American Tobacco's oral tobacco sales, including brands like Velo and Grizzly, are expected to reach 8.3 billion pouches in 2024, reflecting a year-on-year growth of 55%, with U.S. sales surging by 234% [2] Regulatory Developments - The FDA has authorized the sale of 20 ZYN nicotine pouch products, which are deemed to have lower harmful components compared to traditional cigarettes and most smokeless tobacco products, aligning with public health standards [4] - The approval of flavored products is expected to enhance market growth and expand the market's potential [4] Industry Opportunities - Jin Cheng Pharmaceutical is increasing its production capacity to 200 tons per year, focusing on high-purity nicotine for new tobacco products, which positions the company to benefit from the expanding oral tobacco market [5][6] - The company has received various certifications, including FDA PMTA approval, which enhances its competitive edge in the market [6] Investment Recommendations - Companies to watch in the oral tobacco supply chain include Jin Cheng Pharmaceutical (300233.SZ) and Run Du Co., Ltd. (002923.SZ) [7]